Iovance Biotherapeutics, Inc.
IOVA
$3.78
-$0.10-2.58%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -353.86M | -390.98M | -397.63M | -389.92M | -375.36M |
| Total Depreciation and Amortization | 46.67M | 47.19M | 51.71M | 50.17M | 49.10M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 55.92M | 65.51M | 83.07M | 100.40M | 103.84M |
| Change in Net Operating Assets | -19.52M | -24.13M | -60.29M | -64.07M | -111.97M |
| Cash from Operations | -270.79M | -302.41M | -323.14M | -303.41M | -334.39M |
| Capital Expenditure | -34.23M | -33.84M | -28.68M | -20.13M | -13.11M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | 0.00 | 0.00 | 0.00 |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 77.26M | 81.33M | 99.08M | 24.71M | 44.07M |
| Cash from Investing | 43.02M | 47.50M | 70.40M | 4.59M | 30.96M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 257.39M | 307.83M | 254.40M | 214.11M | 354.20M |
| Repurchase of Common Stock | -5.59M | -7.06M | -7.49M | -13.31M | -13.80M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 251.79M | 300.77M | 246.91M | 200.81M | 340.40M |
| Foreign Exchange rate Adjustments | 423.00K | 1.14M | -611.00K | 1.32M | 458.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 24.45M | 47.01M | -6.44M | -96.70M | 37.43M |